IL16 and leukemia: Similar with our findings, decreased level of IL‐16 were observed after Ibrutinib treatment in those patients with chronic lymphocytic leukemia [34], emphasizing that IL‐16 is correlated with disease burden and aberrant immune microenvironment in leukemia patients.